U.S. markets open in 4 hours 8 minutes
  • S&P Futures

    3,698.75
    -33.25 (-0.89%)
     
  • Dow Futures

    29,514.00
    -236.00 (-0.79%)
     
  • Nasdaq Futures

    11,432.75
    -123.00 (-1.06%)
     
  • Russell 2000 Futures

    1,702.70
    -18.10 (-1.05%)
     
  • Crude Oil

    81.83
    -0.32 (-0.39%)
     
  • Gold

    1,654.90
    -15.10 (-0.90%)
     
  • Silver

    18.60
    -0.27 (-1.46%)
     
  • EUR/USD

    0.9675
    -0.0064 (-0.66%)
     
  • 10-Yr Bond

    3.7050
    0.0000 (0.00%)
     
  • Vix

    31.71
    -0.89 (-2.73%)
     
  • GBP/USD

    1.0826
    -0.0060 (-0.55%)
     
  • USD/JPY

    144.7530
    +0.6310 (+0.44%)
     
  • BTC-USD

    19,419.74
    +796.45 (+4.28%)
     
  • CMC Crypto 200

    443.20
    +14.42 (+3.36%)
     
  • FTSE 100

    6,915.42
    -89.97 (-1.28%)
     
  • Nikkei 225

    26,422.05
    +248.07 (+0.95%)
     

Bristol Myers Squibb Announces Dividend

·1 min read

NEW YORK, September 14, 2022--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-four cents ($0.54) per share on the $.10 par value common stock of the company. The dividend is payable on November 1, 2022 to stockholders of record at the close of business on October 7, 2022.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company’s $2.00 convertible preferred stock, payable December 1, 2022, to stockholders of record at the close of business on November 8, 2022.

About Bristol Myers Squibb Company

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.

corporatefinancial-news

View source version on businesswire.com: https://www.businesswire.com/news/home/20220914005905/en/

Contacts

Media:
media@bms.com

Investors:
investor.relations@bms.com